Berkeley Limketkai, MD PhD
@berkeleydoc.bsky.social
Gastroenterologist with clinical and research focuses in IBD, nutrition, data, AI. Serving the world, one gut at a time @UCLAHealth. Views are my own.
Reposted by Berkeley Limketkai, MD PhD
Solomon Scholars Research Day 2025 was a success! Residents across our seven UCLA-affiliated internal medicine programs gathered to share innovative research and case studies. Watch the recap video to learn from some of the presenters about their projects: uclahs.fyi/4moVfyu
May 21, 2025 at 6:06 PM
Solomon Scholars Research Day 2025 was a success! Residents across our seven UCLA-affiliated internal medicine programs gathered to share innovative research and case studies. Watch the recap video to learn from some of the presenters about their projects: uclahs.fyi/4moVfyu
🔥off the press: @amcollegegastro.bsky.social guideline on nutrition/malnutrition for liver disease.
pubmed.gov/40314389
pubmed.gov/40314389
ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease - PubMed
Malnutrition, defined as deficiency, excess, or imbalance of nutrients, is a common complication in patients with liver disease, especially those with cirrhosis. Malnutrition may present as an isolate...
pubmed.gov
May 8, 2025 at 6:34 AM
🔥off the press: @amcollegegastro.bsky.social guideline on nutrition/malnutrition for liver disease.
pubmed.gov/40314389
pubmed.gov/40314389
Mark Baniqued shares our findings of food insecurity among individuals with #IBD in US (13% with #IBD vs. 8% without IBD).
Diet therapies don't work for patients who cannot even afford them.
#DDW2025 @ddwmeeting.bsky.social
Diet therapies don't work for patients who cannot even afford them.
#DDW2025 @ddwmeeting.bsky.social
May 8, 2025 at 1:22 AM
Mark Baniqued shares our findings of food insecurity among individuals with #IBD in US (13% with #IBD vs. 8% without IBD).
Diet therapies don't work for patients who cannot even afford them.
#DDW2025 @ddwmeeting.bsky.social
Diet therapies don't work for patients who cannot even afford them.
#DDW2025 @ddwmeeting.bsky.social
Reposted by Berkeley Limketkai, MD PhD
🚨 Our new commentary in aga-gastro.bsky.social highlights best practices for diagnosing, treating, and monitoring Crohn’s perianal fistula.
📖 Read more: gastro.org/news/best-pr....
#GIsky
📖 Read more: gastro.org/news/best-pr....
#GIsky
April 24, 2025 at 2:05 PM
🚨 Our new commentary in aga-gastro.bsky.social highlights best practices for diagnosing, treating, and monitoring Crohn’s perianal fistula.
📖 Read more: gastro.org/news/best-pr....
#GIsky
📖 Read more: gastro.org/news/best-pr....
#GIsky
Reposted by Berkeley Limketkai, MD PhD
Dr. Dana Lukin provides takeaways from this study published in @aga-gastro.bsky.social that found wearable devices like the Apple Watch and Fitbit may help predict #IBD flares. www.mdedge.com/gihepnews/ar...
April 14, 2025 at 2:03 PM
Dr. Dana Lukin provides takeaways from this study published in @aga-gastro.bsky.social that found wearable devices like the Apple Watch and Fitbit may help predict #IBD flares. www.mdedge.com/gihepnews/ar...
Reposted by Berkeley Limketkai, MD PhD
New research - Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial
www.thelancet.com/journals/lan...
#GastroSky #MedSky #IBDSky
www.thelancet.com/journals/lan...
#GastroSky #MedSky #IBDSky
Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial
Appendicectomy is superior to standard medical therapy alone in maintaining remission
in patients with ulcerative colitis.
www.thelancet.com
April 14, 2025 at 4:40 PM
New research - Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial
www.thelancet.com/journals/lan...
#GastroSky #MedSky #IBDSky
www.thelancet.com/journals/lan...
#GastroSky #MedSky #IBDSky
Reposted by Berkeley Limketkai, MD PhD
🚨 NIH funding changes threaten #GIResearch labs and the future of GI patient care! 🚨 AGA President Maria T. Abreu calls for action. Share your story about how these changes impact your work. Let's protect the future of digestive disease treatment! https://buff.ly/40WPmyC
February 13, 2025 at 10:07 PM
🚨 NIH funding changes threaten #GIResearch labs and the future of GI patient care! 🚨 AGA President Maria T. Abreu calls for action. Share your story about how these changes impact your work. Let's protect the future of digestive disease treatment! https://buff.ly/40WPmyC
Reposted by Berkeley Limketkai, MD PhD
For #IBD folks dealing with pain, this could be a big deal.
www.nature.com/articles/d41...
Lots of data on surgical pain.
Affects sodium channels, not opioid receptors.
Availability and price/coverage TBD.
@ccyanetwork.bsky.social @crohnsandcolitisau.bsky.social @crohnsdiseaseuk.bsky.social
www.nature.com/articles/d41...
Lots of data on surgical pain.
Affects sodium channels, not opioid receptors.
Availability and price/coverage TBD.
@ccyanetwork.bsky.social @crohnsandcolitisau.bsky.social @crohnsdiseaseuk.bsky.social
FDA approves new non-opioid pain drug
Discover the world’s best science and medicine | Nature.com
www.nature.com
January 31, 2025 at 12:29 PM
For #IBD folks dealing with pain, this could be a big deal.
www.nature.com/articles/d41...
Lots of data on surgical pain.
Affects sodium channels, not opioid receptors.
Availability and price/coverage TBD.
@ccyanetwork.bsky.social @crohnsandcolitisau.bsky.social @crohnsdiseaseuk.bsky.social
www.nature.com/articles/d41...
Lots of data on surgical pain.
Affects sodium channels, not opioid receptors.
Availability and price/coverage TBD.
@ccyanetwork.bsky.social @crohnsandcolitisau.bsky.social @crohnsdiseaseuk.bsky.social
Reposted by Berkeley Limketkai, MD PhD
FDA approves mirikizumab for moderately to severely active Crohn’s disease
www.prnewswire.com/news-release...
#GastroSky #MedSky #IDSky
www.prnewswire.com/news-release...
#GastroSky #MedSky #IDSky
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for...
www.prnewswire.com
January 17, 2025 at 6:16 AM
FDA approves mirikizumab for moderately to severely active Crohn’s disease
www.prnewswire.com/news-release...
#GastroSky #MedSky #IDSky
www.prnewswire.com/news-release...
#GastroSky #MedSky #IDSky
Reposted by Berkeley Limketkai, MD PhD
The spread of health misinformation and disinformation poses a serious threat to public health.
How can we respond to the danger and combat the tide of misinformation and disinformation to protect public health?
Find out more in our latest Editorial: tinyurl.com/mtf95p25
How can we respond to the danger and combat the tide of misinformation and disinformation to protect public health?
Find out more in our latest Editorial: tinyurl.com/mtf95p25
January 17, 2025 at 12:11 PM
The spread of health misinformation and disinformation poses a serious threat to public health.
How can we respond to the danger and combat the tide of misinformation and disinformation to protect public health?
Find out more in our latest Editorial: tinyurl.com/mtf95p25
How can we respond to the danger and combat the tide of misinformation and disinformation to protect public health?
Find out more in our latest Editorial: tinyurl.com/mtf95p25
Reposted by Berkeley Limketkai, MD PhD
🌟 Our new clinical practice update on endoscopic enteral access is out! Discover the best practices for tube selection, access points, and feeding methods for patients with inadequate oral intake. #GIsky #ClinicalPracticeUpdate
January 9, 2025 at 4:00 PM
🌟 Our new clinical practice update on endoscopic enteral access is out! Discover the best practices for tube selection, access points, and feeding methods for patients with inadequate oral intake. #GIsky #ClinicalPracticeUpdate
Reposted by Berkeley Limketkai, MD PhD
Say hello to @aga-gihn.bsky.social, AGA's official newspaper, on bsky and follow for articles on the latest in GI!
Hi #GIsky! GI & Hepatology News, the official newspaper of
@amergastroassn.bsky.social, is now on #bsky! Keep up with our latest articles 📰➡️
@amergastroassn.bsky.social, is now on #bsky! Keep up with our latest articles 📰➡️
GI and Hepatology News | MDedge
The Official Newspaper of the AGA Institute
buff.ly
December 11, 2024 at 8:20 PM
Say hello to @aga-gihn.bsky.social, AGA's official newspaper, on bsky and follow for articles on the latest in GI!
Too bad filgotinib was not superior for all wk 10 primary endpoints for #CD. This may have partly been due to mandatory steroid tapering not starting until wk 14 (unlike U-EXCEL/U-EXCEED upadacitinib trials that started at wk 4).
Filgotinib will now have a higher bar to climb for positioning.
Filgotinib will now have a higher bar to climb for positioning.
JAK Inhibitor Comes Up Short in Phase III Crohn's Disease Trial
www.medpagetoday.com/gastroentero... via @medpagetoday.bsky.social #GastroSky #MedSky #IBDSky
www.medpagetoday.com/gastroentero... via @medpagetoday.bsky.social #GastroSky #MedSky #IBDSky
JAK Inhibitor Comes Up Short in Phase III Crohn's Disease Trial
Investigational drug filgotinib demonstrated limited efficacy in DIVERSITY study
www.medpagetoday.com
December 9, 2024 at 12:17 AM
Too bad filgotinib was not superior for all wk 10 primary endpoints for #CD. This may have partly been due to mandatory steroid tapering not starting until wk 14 (unlike U-EXCEL/U-EXCEED upadacitinib trials that started at wk 4).
Filgotinib will now have a higher bar to climb for positioning.
Filgotinib will now have a higher bar to climb for positioning.
Reposted by Berkeley Limketkai, MD PhD
🆕 AGA living guideline for moderate-to-severe #UlcerativeColitis. ⤵️
Sidd Singh, @berkeleydoc.bsky.social, @manasiagrawal.bsky.social, @jhaydek.bsky.social, @ashwinmdibd.bsky.social, @frankiscottmd.bsky.social & Edward Loftus rank 1️⃣2️⃣ therapies by efficacy.
gastro.org/clinical-gui...
Sidd Singh, @berkeleydoc.bsky.social, @manasiagrawal.bsky.social, @jhaydek.bsky.social, @ashwinmdibd.bsky.social, @frankiscottmd.bsky.social & Edward Loftus rank 1️⃣2️⃣ therapies by efficacy.
gastro.org/clinical-gui...
Living guideline for moderate-to-severe ulcerative colitis
New clinical guideline on pharmacological management of moderate-to-severe ulcerative colitis.
gastro.org
November 26, 2024 at 3:54 PM
🆕 AGA living guideline for moderate-to-severe #UlcerativeColitis. ⤵️
Sidd Singh, @berkeleydoc.bsky.social, @manasiagrawal.bsky.social, @jhaydek.bsky.social, @ashwinmdibd.bsky.social, @frankiscottmd.bsky.social & Edward Loftus rank 1️⃣2️⃣ therapies by efficacy.
gastro.org/clinical-gui...
Sidd Singh, @berkeleydoc.bsky.social, @manasiagrawal.bsky.social, @jhaydek.bsky.social, @ashwinmdibd.bsky.social, @frankiscottmd.bsky.social & Edward Loftus rank 1️⃣2️⃣ therapies by efficacy.
gastro.org/clinical-gui...
Reposted by Berkeley Limketkai, MD PhD
Real-world data of JAK-inhs from Japan, comparing UPA, FIL and TOF
- UPA seems to be most effective, even in pts with previous exposure to ≥2 advanced therapies
- UPA: acne is quite common (23%), a relevant side-effect for some patients
- FIL = TOF
#IBDSky
onlinelibrary.wiley.com/doi/10.1111/...
- UPA seems to be most effective, even in pts with previous exposure to ≥2 advanced therapies
- UPA: acne is quite common (23%), a relevant side-effect for some patients
- FIL = TOF
#IBDSky
onlinelibrary.wiley.com/doi/10.1111/...
November 24, 2024 at 2:30 PM
Real-world data of JAK-inhs from Japan, comparing UPA, FIL and TOF
- UPA seems to be most effective, even in pts with previous exposure to ≥2 advanced therapies
- UPA: acne is quite common (23%), a relevant side-effect for some patients
- FIL = TOF
#IBDSky
onlinelibrary.wiley.com/doi/10.1111/...
- UPA seems to be most effective, even in pts with previous exposure to ≥2 advanced therapies
- UPA: acne is quite common (23%), a relevant side-effect for some patients
- FIL = TOF
#IBDSky
onlinelibrary.wiley.com/doi/10.1111/...
Reposted by Berkeley Limketkai, MD PhD
🎨 In case anyone need…
The NIH BioArt Source is an awesome library of *free* professionally drawn illustrations for scientific presentations or figures. Downloadable in HD. Thank you NIH for this invaluable tool 🙏!
Check it out 👇
bioart.niaid.nih.gov
The NIH BioArt Source is an awesome library of *free* professionally drawn illustrations for scientific presentations or figures. Downloadable in HD. Thank you NIH for this invaluable tool 🙏!
Check it out 👇
bioart.niaid.nih.gov
November 23, 2024 at 3:50 PM
🎨 In case anyone need…
The NIH BioArt Source is an awesome library of *free* professionally drawn illustrations for scientific presentations or figures. Downloadable in HD. Thank you NIH for this invaluable tool 🙏!
Check it out 👇
bioart.niaid.nih.gov
The NIH BioArt Source is an awesome library of *free* professionally drawn illustrations for scientific presentations or figures. Downloadable in HD. Thank you NIH for this invaluable tool 🙏!
Check it out 👇
bioart.niaid.nih.gov
AGA has joined the party. Welcome!
Hi #GIsky! 👋 The #AGAGastroSquad is on #bsky and we're excited to connect with so many of you on a new platform! Come say hi and let your friends know we're here!
#GastroSky #LiverSky #IBDSky
#GastroSky #LiverSky #IBDSky
November 23, 2024 at 4:44 AM
AGA has joined the party. Welcome!
Reposted by Berkeley Limketkai, MD PhD
Early bird rate for #CCCongress25 ends on Wednesday ⏰
🐐 @umamahadevanibd.bsky.social keynote on IBD & 🤰
👩🏫 #IBD A-Z
💪 Surgery prehabilitation
🚨Ultrasound training course with #IUSCAN #IBUS
@edelblumlab.bsky.social
#AGA
crohnscolitiscongress.org
🐐 @umamahadevanibd.bsky.social keynote on IBD & 🤰
👩🏫 #IBD A-Z
💪 Surgery prehabilitation
🚨Ultrasound training course with #IUSCAN #IBUS
@edelblumlab.bsky.social
#AGA
crohnscolitiscongress.org
November 21, 2024 at 8:28 PM
Early bird rate for #CCCongress25 ends on Wednesday ⏰
🐐 @umamahadevanibd.bsky.social keynote on IBD & 🤰
👩🏫 #IBD A-Z
💪 Surgery prehabilitation
🚨Ultrasound training course with #IUSCAN #IBUS
@edelblumlab.bsky.social
#AGA
crohnscolitiscongress.org
🐐 @umamahadevanibd.bsky.social keynote on IBD & 🤰
👩🏫 #IBD A-Z
💪 Surgery prehabilitation
🚨Ultrasound training course with #IUSCAN #IBUS
@edelblumlab.bsky.social
#AGA
crohnscolitiscongress.org
Hot🔥 off the press! Living guidelines for pharmacological treatment of #UC
@jhaydek.bsky.social presents an excellent skytorial
@jhaydek.bsky.social presents an excellent skytorial
November 20, 2024 at 12:12 AM
Hot🔥 off the press! Living guidelines for pharmacological treatment of #UC
@jhaydek.bsky.social presents an excellent skytorial
@jhaydek.bsky.social presents an excellent skytorial
Reposted by Berkeley Limketkai, MD PhD
The AGA’s first-ever living guideline formoderate-to-severe #UlcerativeColitis led by S Singh, @berkeleydoc.bsky.social, @manasiagrawal.bsky.social, @jhaydek.bsky.social , @ashwinmdibd, @EdwardLoftus2 and myself prioritizes early use of advanced txs over a step-up approach.
ow.ly/t2Ru50UahEi
ow.ly/t2Ru50UahEi
DEFINE_ME
ow.ly
November 19, 2024 at 7:47 PM
The AGA’s first-ever living guideline formoderate-to-severe #UlcerativeColitis led by S Singh, @berkeleydoc.bsky.social, @manasiagrawal.bsky.social, @jhaydek.bsky.social , @ashwinmdibd, @EdwardLoftus2 and myself prioritizes early use of advanced txs over a step-up approach.
ow.ly/t2Ru50UahEi
ow.ly/t2Ru50UahEi
Reposted by Berkeley Limketkai, MD PhD
Towards better understanding how we should position advanced tx in UC:
Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis - Gastroenterology www.gastrojournal.org/article/S001...
Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis - Gastroenterology www.gastrojournal.org/article/S001...
November 12, 2024 at 10:38 PM
Towards better understanding how we should position advanced tx in UC:
Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis - Gastroenterology www.gastrojournal.org/article/S001...
Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis - Gastroenterology www.gastrojournal.org/article/S001...
And so begins my journey in this new community. Hopefully, Blue Sky lives up to its name. 😊
November 16, 2024 at 6:49 AM
And so begins my journey in this new community. Hopefully, Blue Sky lives up to its name. 😊